Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

06 juin 2016 08h00 HE | Source: BeiGene, LTD.

BeiGene to Participate in Goldman Sachs 37th Annual Global Healthcare Conference

WALTHAM, Mass., June 06, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (Nasdaq:BGNE), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology...
05 juin 2016 09h00 HE | Source: BeiGene, LTD.

BeiGene Presents Initial Clinical Data on PD-1 Antibody BGB-A317 at the 2016 American Society of Clinical Oncology Annual Meeting

WALTHAM, Mass., June 05, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and...
19 mai 2016 06h00 HE | Source: BeiGene, LTD.

BeiGene Announces Presentation on BGB-A317 at the 2016 American Society of Clinical Oncology Annual Meeting

WALTHAM, Mass., May 19, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology...
11 mai 2016 16h15 HE | Source: BeiGene, LTD.

BeiGene Reports First Quarter 2016 Financial Results

WALTHAM, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology...
04 mai 2016 17h24 HE | Source: BeiGene, LTD.

BeiGene Appoints Dr. Ji Li as Executive Vice President, Global Head of Business Development

WALTHAM, Mass., May 04, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE) (“BeiGene”), a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology...
17 avr. 2016 17h15 HE | Source: BeiGene, LTD.

BeiGene Presents Clinical Data for RAF Dimer Inhibitor BGB-283 at the 2016 American Association for Cancer Research Annual Meeting

WALTHAM, Mass., April 17, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE) (“BeiGene”), a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and...
11 avr. 2016 17h00 HE | Source: BeiGene, LTD.

BeiGene Appoints Eric Hedrick, M.D. as Interim Chief Medical Officer

WALTHAM, Mass., April 11, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE) (“BeiGene”), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and...
30 mars 2016 16h05 HE | Source: BeiGene, LTD.

BeiGene Reports Fourth Quarter and Full Year 2015 Financial Results

WALTHAM, Mass., March 30, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE) (“BeiGene”), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and...
16 mars 2016 17h48 HE | Source: BeiGene, LTD.

BeiGene Announces Presentations on BGB-283 and Other Pipeline Agents at the 2016 American Association for Cancer Research Annual Meeting

WALTHAM, Mass., March 16, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE) (“BeiGene”), a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and...
07 mars 2016 08h00 HE | Source: BeiGene, LTD.

BeiGene Receives Approval to Initiate Clinical Trials in China With BGB-3111

BEIJING, March 07, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (Nasdaq:BGNE), (“BeiGene”) a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncological...

Page précédente